Earnings Outlook For Trevi Therapeutics
Portfolio Pulse from Benzinga Insights
Trevi Therapeutics (NASDAQ:TRVI) is scheduled to release its quarterly earnings report on March 20, 2024, with analysts expecting an EPS of $-0.09. The company's past earnings performance shows a pattern of beating EPS estimates but experiencing varied stock price reactions post-announcement. Shares are currently trading at $3.25, reflecting an 82.78% increase over the last 52 weeks. Investors are looking for positive guidance for the next quarter beyond the EPS figures.
March 19, 2024 | 4:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Trevi Therapeutics is expected to announce an EPS of $-0.09 for the latest quarter, with a history of beating estimates but mixed stock price reactions. Shares have significantly appreciated over the past year.
Given Trevi Therapeutics' history of beating EPS estimates but experiencing mixed reactions in stock price, the short-term impact is uncertain. The stock's significant year-to-date appreciation suggests a positive long-term outlook, but the immediate reaction to the upcoming earnings report will likely depend on the provided future guidance and how it compares to past performance.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100